Valneva

Valneva shares jumped nearly 23% and climbed back above the 200-day moving average, cutting the year-to-date loss to 19%. The move follows positive Phase III data for the tick vaccine PF-07307405, developed with Pfizer; the European Medicines Agency is now reviewing it for approval. Jefferies analyst Maury Raycroft also sees FDA approval of the U.S. filing as likely and assigns a $15 price target to the U.S. warrants. » More on de.investing.com

Valneva reports a net loss of €63.3m for H1 2026, worsened gross margins, declining travel vaccine sales and one‑off charges, which caused revenue and operating profit to decline. The company lowered its 2026 product sales forecast to €135–150m and total revenue to €145–160m, citing weakening demand in key markets. The share price came under pressure after the report, while progress on the restructuring and the Lyme disease programme with Pfizer are seen as longer‑term catalysts. » More on de.investing.com

Valneva reported Q4 2025 EPS of -$0.24 (forecast -$0.3693) and revenue of $55.17m (expectation $50.56m); the stock rose 2.82% in pre-market trading to $11.32. The full-year results show total revenue of over €170m and a 9% increase in sales of its own products, while operating loss (€82.1m) and net loss (€115.2m) were weighed down by higher R&D spending. Valneva emphasizes focus on its vaccine portfolio, notably Lyme disease and chikungunya, expects Phase-3 data for Lyme disease in H1 2026 and forecasts revenue of around $204.39m for 2026. Risks remain regulatory approvals, market acceptance and geopolitical/structural challenges. » More on de.investing.com